Who Is (and Isn't) a Candidate for GLP-1 Medications
A plain-language look at who fits the eligibility criteria for weight-management drugs like Wegovy and Zepbound — and who the labels say should not take them.
By Wellness Wire Editorial
Medications known as GLP-1 receptor agonists — and the newer dual GIP/GLP-1 agonists — have moved from diabetes clinics into mainstream conversations about weight. Two are central to that story: semaglutide, sold for weight management as Wegovy, and tirzepatide, sold as Zepbound. They can be effective, but they are not for everyone. Eligibility is set by U.S. Food and Drug Administration (FDA) labeling, tested in large clinical trials, and bounded by a short list of safety rules. Here is who fits those criteria — and who, according to the labels, should not take these drugs.
What these medications are for
Both Wegovy and Zepbound are FDA-approved for chronic weight management. Zepbound is indicated for adults with obesity, or for adults who are overweight and also have a weight-related health problem. Wegovy carries a similar weight-management indication for adults and, notably, extends to some adolescents. Over time both labels have grown to cover more than weight alone — something we return to below. Because the labels differ in their details, and because Wegovy now comes in more than one form, the two drugs are not simply interchangeable.
The BMI-and-health rules
The core eligibility test combines body-mass index (BMI) with health status. For adults, both drugs' labels describe two doorways in — one based on weight alone, and one that pairs a lower weight threshold with an existing health condition.
- A BMI of 30 or higher (obesity), on its own; or
- A BMI from 27 up to just under 30 (overweight) plus at least one weight-related condition. Zepbound's label names dyslipidemia (unhealthy cholesterol or blood fats), high blood pressure, type 2 diabetes, obstructive sleep apnea, and cardiovascular disease as qualifying conditions.
Wegovy reaches further than Zepbound in one respect: it is also indicated for children aged 12 and older with obesity, defined for that age group as a BMI at or above the 95th percentile for a child's age and sex. In the evidence reviewed here, Zepbound's weight-management indication is for adults.
Professional guidance broadly tracks the labels. The American Diabetes Association's Standards of Care use the same BMI thresholds — 30 or higher, or 27 or higher with an obesity-associated condition such as type 2 diabetes, high blood pressure, or dyslipidemia — and name semaglutide and tirzepatide among preferred options for their greater weight-loss effect, while advising that treatment be continued rather than stopped once goals are met. This particular guideline point comes from a summary of the standards rather than the full document, so it is worth confirming with a clinician.
Meeting the BMI cutoff is a doorway, not a guarantee — the labels set eligibility, not a promise of benefit for any one person.
Beyond weight: other paths to eligibility
Eligibility is no longer only about the number on the scale. Large trials have opened additional, more specific reasons a person might be a candidate.
- Heart protection. In the SELECT trial of more than 17,000 adults aged 45 and older who had established cardiovascular disease and were overweight or obese — but did not have diabetes — semaglutide 2.4 mg cut the risk of major cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) by 20% versus placebo, alongside about 9.4% average weight loss. Wegovy now carries an indication to reduce those events in this group.
- Obstructive sleep apnea. Zepbound is separately approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. In the SURMOUNT-OSA trials, tirzepatide reduced the apnea-hypopnea index — a measure of breathing interruptions during sleep — far more than placebo, whether or not people also used a breathing (PAP) machine.
- Liver disease. Wegovy's newer labeling adds an indication for MASH — a form of fatty liver disease — with liver fibrosis.
There is also more than one way to take these drugs. Most attention goes to weekly injections, but oral options now exist too. The OASIS 1 trial tested a once-daily oral semaglutide tablet at 50 mg in adults with overweight or obesity, with average weight loss of about 15% at 68 weeks. In December 2025, the FDA approved an oral semaglutide (Wegovy) tablet for chronic weight management in adults — a non-injectable option — though at a lower dose than the 50 mg studied in OASIS 1. Oral and injectable products are not automatically interchangeable, so the specific form and dose are a prescriber's call.
Who isn't a candidate
Some people should not take these medications at all. The labels list two firm contraindications.
- A personal or family history of medullary thyroid carcinoma (a specific thyroid cancer), or the genetic syndrome multiple endocrine neoplasia type 2 (MEN 2). Both drugs carry a boxed warning — the FDA's strongest — based on thyroid tumors seen in rodents. Whether that risk applies to humans is not established, but the contraindication stands.
- A history of serious allergic reaction to the medication.
One common worry deserves a careful answer. A past episode of pancreatitis is not, by itself, a formal contraindication in these labels. It appears instead as a warning: acute pancreatitis — sometimes severe — has been reported with GLP-1 medications, and the drug should be stopped if pancreatitis is suspected. That is a reason for caution and a conversation with a prescriber, not an automatic disqualification.
The labels and guidelines flag other considerations as well, and a prescriber weighs factors this article did not examine. Meeting the criteria on paper is where the conversation starts, not where it ends.
What the numbers can — and can't — tell you
The trials that defined these groups also showed how much weight people lost. In STEP 1, adults without diabetes lost about 14.9% of their body weight on semaglutide 2.4 mg at 68 weeks, versus 2.4% on placebo. In SURMOUNT-1, adults lost roughly 15% to 21% on tirzepatide depending on the dose, versus about 3% on placebo — and more than half of those on the highest dose lost at least a fifth of their body weight.
Two cautions matter. First, these pivotal weight-loss trials enrolled adults without diabetes; the drugs were studied separately in people with type 2 diabetes, which this piece did not examine. Second, a BMI cutoff is an eligibility line, not a personal forecast: it does not guarantee that any individual will benefit from or tolerate the drug. Whether one of these medications is right for you depends on your full health picture and a licensed prescriber's judgment.
- 01 Zepbound (tirzepatide) FDA Prescribing Information, via DailyMed, 2024 dailymed.nlm.nih.gov ↗Indications & Usage; Contraindications; Warnings & Precautions — adult obesity/overweight-plus-comorbidity (hypertension, dyslipidemia, type 2 diabetes, OSA, cardiovascular disease) and OSA indications, MTC/MEN 2 contraindication, pancreatitis warning.
- 02 Wegovy (semaglutide) FDA Prescribing Information, via DailyMed, 2025 dailymed.nlm.nih.gov ↗Indications & Usage; Contraindications — adult and adolescent (12+) weight indications, cardiovascular and MASH indications, MTC/MEN 2 contraindication and boxed warning.
- 03 STEP 1 trial (Wilding et al., NEJM), via WikiJournalClub, 2021 wikijournalclub.org ↗Pivotal obesity efficacy: semaglutide 2.4 mg, -14.9% vs -2.4% placebo at week 68 in adults without diabetes.
- 04 SURMOUNT-1 trial (Jastreboff et al., NEJM), PubMed, 2022 pubmed.ncbi.nlm.nih.gov ↗Tirzepatide dose-response in obesity: -15.0% to -20.9% vs -3.1% placebo at 72 weeks; 57% on the 15 mg dose reached >=20% weight loss.
- 05 Secondary CV prevention: 20% reduction in major adverse cardiovascular events (HR 0.80) in 17,604 adults >=45 with established CVD and overweight/obesity, without diabetes; mean weight change -9.4%.
- 06 SURMOUNT-OSA trials (Malhotra et al., NEJM), PubMed Central, 2024 pmc.ncbi.nlm.nih.gov ↗Basis for the OSA indication: tirzepatide reduced the apnea-hypopnea index far more than placebo, with and without PAP therapy.
- 07 Oral semaglutide 50 mg once daily (trial dose): -15.1% vs -2.4% placebo at week 68 in adults with overweight/obesity.
- 08 ADA Standards of Care in Diabetes 2026, Section 8, 2026 diabetesjournals.org ↗Aligns candidacy with FDA BMI thresholds; names semaglutide and tirzepatide as preferred options and advises continuing therapy once targets are met. Lower-confidence: drawn from a summary, not the full text.
- 09 FDA approved once-daily oral semaglutide (25 mg) for chronic weight management and MACE risk reduction in adults; the marketed oral dose is lower than the 50 mg tested in OASIS 1. Reported via Novo Nordisk company announcement and AJMC, Dec 2025.
Wellness Wire Editorial
The Wellness Wire editorial team. Our explainers are researched from primary sources — clinical-trial reports and FDA labeling — and written for general education. They are not individually reviewed by a clinician and are not a substitute for medical advice.
